Navigation Links
GenePaint from Tecan

ProductsGenePaint from Tecan
Company Tecan
Item GenePaint
Price 
Description Tecans GenePaint system, which is based on a new flow-through technology, automates all of the steps required for performing in situ hybridization of tissues on microscope slide formats.

A key step in the study of gene expression, in situ hybridization (ISH) localizes transcripts in intact cells and tissues and can be used to validate and confirm results obtained by in vitro gene expression methods (microarrays, blots, etc.). GenePaint automates the processing of large numbers of cell or tissue samples in these type of procedures; an otherwise extremely time consuming and laborious manual process.

Advanced features for functional genomic studies include:
  • eliminates 80% of the manual steps of conventional ISH, FISH or IHC analysis
  • extends walk-away time through unattended hybridization protocols
  • allows the use of any commercial set of reagents for hybridization studies
  • assures consistent and reproducible results of excellent quality
  • saves on the amounts of reagents used
  • The applications described here are not available in the US outside of the research market.
    Info TecanTecan
    Tecan U.S., Inc.
    4022 Stirrup Creek Road
    Suite 310
    Durham, NC 27703

    Customer Service: (800) 338-3226
    Fax Number: (919) 361-5201
    Web Site: http://www.tecan.com
    NOTE: Price information is approximate list price and actual prices may vary.

    Related biology products :

    1. Connect from Tecan
    2. Freedom EVOlyzer from Tecan
    3. ELISA Biopharma from Tecan
    4. HS 4800 Hybridization Station from Tecan
    5. HS 400 Hybridization Station from Tecan
    6. Freedom EVO Clinical from Tecan
    7. Freedom EVO 150 from Tecan
    8. TRAC Tecan Robotic Assay Composer from Tecan
    9. Aquarius 384 Multichannel Pipettor from Tecan
    10. Freedom EVOware from Tecan
    11. Columbus from Tecan
    Applications: ISH...
    ... Immunogen: Recombinant human IDO ... for the ~44 kDa human ... (positive control: IFN-Gamma-stimmulated Human peripheral ... homology reactivity with mouse and ...
    ...
    TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
    Biology Products:
    (Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
    (Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
    (Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
    Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
    ... you,ve owned a pet guppy, you know they often jump out ... jumped; many a parent has been stumped for an answer. ... how guppies are able to jump so far, and suggests why ... that controls animal behavior, decided to study jumping guppies while researching ...
    ... Electronics group have come up with a novel solution ... organic semiconductor industry today. Oana Jurchescu, an assistant professor ... high performance organic semiconductor ,spray paint, that can be ... This is a potentially game changing technology for a ...
    ... reduced mortality in a mouse model of the neurodegenerative ... according to a new study by researchers at the ... published online ahead of print in the journal ... for melatonin are found in the nerve cells, a ...
    Cached Biology News:Why do guppies jump? 2High performance semiconductor spray paint could be a game changer for organic electronics 2Pitt team finds melatonin delays ALS symptom onset and death in mice 2
    (Date:4/27/2015)... Philadelphia, PA (PRWEB) April 27, 2015 ... Phelix Therapeutics, the newest resident of the University ... Market Street in Philadelphia. , With a $4.5 ... of Health in hand, Phelix Therapeutics is ... is developing nutritional supplements. The company is developing first-in-class ...
    (Date:4/27/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) ... 2015 of $226.5 million, down 6%.  Excluding currency ... The Company reported a fourth quarter GAAP net ... Adjusted net income, exclusive of transformation, restructuring and ... up 1%, and adjusted earnings per share were ...
    (Date:4/27/2015)... Diasome Pharmaceuticals, Inc. (“Diasome”) has announced ... Center (“Joslin”) to collaborate on the design of ... Directed Vesicle (“HDV”) targeting system for insulin in ... in Boston, Massachusetts, Joslin is the world's leading ... to the prevention, treatment and cure of diabetes. ...
    (Date:4/24/2015)... 24, 2015 The South Dakota School ... have entered into an agreement to promote cooperation on ... agreement signed by the universities will encourage and promote ... other services particularly, though not exclusively, relating to sustainability, ... strengths and a similar set of values,” said Michael ...
    Breaking Biology Technology:New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 31Diasome Pharmaceuticals Announces Clinical Trial Design Collaboration 2South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2